Bram ten Cate

429 total citations
8 papers, 356 citations indexed

About

Bram ten Cate is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Bram ten Cate has authored 8 papers receiving a total of 356 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 3 papers in Hematology and 2 papers in Oncology. Recurrent topics in Bram ten Cate's work include Cell death mechanisms and regulation (6 papers), RNA Interference and Gene Delivery (3 papers) and Acute Myeloid Leukemia Research (2 papers). Bram ten Cate is often cited by papers focused on Cell death mechanisms and regulation (6 papers), RNA Interference and Gene Delivery (3 papers) and Acute Myeloid Leukemia Research (2 papers). Bram ten Cate collaborates with scholars based in Netherlands, Germany and United States. Bram ten Cate's co-authors include Wijnand Helfrich, Edwin Bremer, Douwe F. Samplonius, Lou F. M. H. de Leij, Theo Bijma, Marco de Bruyn, Alja J. Stel, Georg H. Fey, Julia Stieglmaier and Gerwin Huls and has published in prestigious journals such as Blood, The Journal of Immunology and Cancer Research.

In The Last Decade

Bram ten Cate

8 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bram ten Cate Netherlands	8	239	152	105	84	44	8	356
Carina Olsson Switzerland	8	169 0.7×	294 1.9×	71 0.7×	102 1.2×	16 0.4×	9	434
Angéla Virone-Oddos France	11	185 0.8×	89 0.6×	144 1.4×	81 1.0×	43 1.0×	30	376
Claire Harris United Kingdom	9	354 1.5×	51 0.3×	131 1.2×	46 0.5×	19 0.4×	15	442
Nancy H. Jones United States	7	162 0.7×	221 1.5×	75 0.7×	114 1.4×	23 0.5×	8	401
Joaquina Mascarenhas United States	3	237 1.0×	78 0.5×	71 0.7×	31 0.4×	39 0.9×	3	322
James W. Rohrer United States	14	192 0.8×	327 2.2×	104 1.0×	182 2.2×	115 2.6×	18	483
Erlina S. Pali United States	7	350 1.5×	192 1.3×	118 1.1×	33 0.4×	13 0.3×	7	517
Selvi Ramasamy United States	5	256 1.1×	156 1.0×	100 1.0×	54 0.6×	13 0.3×	8	377
Siddhartha Sen United States	11	284 1.2×	90 0.6×	106 1.0×	21 0.3×	93 2.1×	15	410
Silvana Pessano United States	9	204 0.9×	205 1.3×	78 0.7×	145 1.7×	94 2.1×	12	449

Countries citing papers authored by Bram ten Cate

Since Specialization

Citations

This map shows the geographic impact of Bram ten Cate's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bram ten Cate with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bram ten Cate more than expected).

Fields of papers citing papers by Bram ten Cate

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bram ten Cate. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bram ten Cate. The network helps show where Bram ten Cate may publish in the future.

Co-authorship network of co-authors of Bram ten Cate

This figure shows the co-authorship network connecting the top 25 collaborators of Bram ten Cate. A scholar is included among the top collaborators of Bram ten Cate based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bram ten Cate. Bram ten Cate is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Cate, Bram ten, Edwin Bremer, Marco de Bruyn, et al.. (2009). A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia. 23(8). 1389–1397. 50 indexed citations

Cate, Bram ten, Marco de Bruyn, Edwin Bremer, et al.. (2009). Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology. Current Drug Targets. 11(1). 95–110. 32 indexed citations

Bremer, Edwin, Marco de Bruyn, Douwe F. Samplonius, et al.. (2008). Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells. Journal of Molecular Medicine. 86(8). 909–924. 26 indexed citations

Bremer, Edwin, Bram ten Cate, Douwe F. Samplonius, et al.. (2008). Superior Activity of Fusion Protein scFvRit:sFasL over Cotreatment with Rituximab and Fas Agonists. Cancer Research. 68(2). 597–604. 41 indexed citations

Stel, Alja J., Bram ten Cate, S. Jacobs, et al.. (2007). Fas Receptor Clustering and Involvement of the Death Receptor Pathway in Rituximab-Mediated Apoptosis with Concomitant Sensitization of Lymphoma B Cells to Fas-Induced Apoptosis. The Journal of Immunology. 178(4). 2287–2295. 69 indexed citations

Stieglmaier, Julia, Edwin Bremer, Christian Kellner, et al.. (2007). Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunology Immunotherapy. 57(2). 233–246. 53 indexed citations

Cate, Bram ten, Douwe F. Samplonius, Theo Bijma, et al.. (2006). The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia. 21(2). 248–252. 37 indexed citations

Bremer, Edwin, Bram ten Cate, Douwe F. Samplonius, Lou F. M. H. de Leij, & Wijnand Helfrich. (2005). CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood. 107(7). 2863–2870. 48 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact